WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005034963) USE OF GINSENOSIDES Rh2 & Rg3, AND AGLYCON GINSENOSIDES FOR THE PREVENTION OF CANCER
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/034963    International Application No.:    PCT/CA2004/001824
Publication Date: 21.04.2005 International Filing Date: 15.10.2004
IPC:
A61K 31/575 (2006.01), A61K 31/704 (2006.01)
Applicants: PANAGIN PHARMACEUTICALS INC. [CA/CA]; 112 - 11800 River Road, Richmond, British Columbia V6X 1Z7 (CA) (For All Designated States Except US).
HUANG, Winter [CA/CA]; (CA) (For US Only).
JIA, William [CA/CA]; (CA) (For US Only)
Inventors: HUANG, Winter; (CA).
JIA, William; (CA)
Agent: SMITH, Paul; Paul Smith Intellectual Property Law, Suite 330 - 1508 West Broadway, Vancouver, British Columbia V6J 1W8 (CA)
Priority Data:
60/511,129 15.10.2003 US
Title (EN) USE OF GINSENOSIDES Rh2 & Rg3, AND AGLYCON GINSENOSIDES FOR THE PREVENTION OF CANCER
(FR) UTILISATION DE GINSENOSIDES RH2 & RG3, ET GINSENOSIDES D'AGLYCONE DANS LA PREVENTION DE CANCER
Abstract: front page image
(EN)This invention pertains to a method of preventing cancer in humans or other animals by administering to the human or other animals ginsenosides Rh2, Rh3, aglycon ginsenosides, or any combination thereof. These ginsenosides and aglycon ginsenosides prevent or reduce the chances of developing cancer or precancerous malignancies by inhibiting the activities of cytochrome p450 enzymes. This invention also pertains to pharmaceutical and non­pharmaceutical compositions for the prevention of cancer in humans or other animals.
(FR)L'invention concerne une méthode de prévention de cancer chez des êtres humains ou d'autres animaux par administration de ginsenosides Rh2, Rh3, de ginsenosides d'aglycone ou de toute combinaison associée à des êtres humains ou à des animaux. Ces ginsenosides et ginsenosides d'aglycone permettent de prévenir ou de diminuer les risques de développer un cancer ou des malignités précancéreuses par inhibition des activités des enzymes p450 de cytochrome. Ladite invention a également pour objet des compositions pharmaceutiques et non pharmaceutiques dans la prévention de cancer chez des êtres humains ou d'autres animaux.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)